SCLC: elderly patients survive longer with aggressive therapy

  • Clin Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients aged ≥80 years who received more aggressive therapy for SCLC had better survival than those who received chemotherapy alone, local therapy alone, or no treatment.
  • Nearly one-third of patients did not receive treatment.

Why this matters

  • Elderly patients are a growing population among SCLC cases, but data on treatment and outcomes are lacking, as they are rarely included in clinical trials.

Study design

  • 146 patients from the Institutional Lung Cancer Database who were ≥80 years at SCLC diagnosis.
  • Funding: None.

Key results

  • 32% had limited-stage SCLC and 68% had extensive-stage disease.
  • 30% of patients received no therapy, 44.5% received chemotherapy alone, 18.5% received chemotherapy plus radiotherapy and/or surgery (local therapy), and 7% received local therapy alone.
  • Median OS for the entire cohort was 5.4 months.
  • After multivariable analysis, disease stage (P=.011), performance score (P=.029), and treatment option (P<.0001 were significantly associated with os.>
  • Median OS was 1.3 months without active therapy, 6 months with local therapy alone, 7.2 months with chemotherapy alone, and 14.4 months with chemotherapy plus local therapy.
  • After multivariable analysis, only the treatment option remained significant for survival among patients with limited-stage (P=.0001) and extensive-stage (P<.0001 disease.>

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit